Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.63 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998468 | 1.00 | SLC5A2 (0.63) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL4000404 | 0.88 | SLC5A2 (0.70) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL4000420 | 0.88 | SLC5A2 (0.70) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL4007533 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL2574895 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL4001101 | 0.82 | SLC5A2 (0.73) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL4001106 | 0.82 | SLC5A2 (0.73) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL3999445 | 0.82 | SLC5A2 (0.60) | SLC5A2SLC5A1ACHE | |
| SCHEMBL3999454 | 0.82 | SLC5A2 (0.60) | SLC5A2SLC5A1ACHE | |
| SCHEMBL2577633 | 0.81 | SLC5A2 (0.74) | SLC5A2SLC5A1ACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541341-B2 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7129381-B2 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-7053060-B2 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| EP-1367060-B1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20050113315-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| US-20050059614-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2005-03-17 | — | — | US | disclosed |
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040063170-A1 | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1367060-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1344780-A1 | GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885ACHE 3360/4885 |
| US-20050113315-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 3186/4885 |
| US-20050059614-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.